Dual-BTD psilocybin analog in two Phase 3 pivotals for MDD, but a $42M/quarter burn means survival to NDA hinges on APPROACH data and follow-on financing

Helus Pharma is a clinical-stage company developing a psilocybin-based drug for major depressive disorder that is not yet approved, and it is currently running two Phase 3 trials while burning through cash at a rate that makes survival dependent on positive data and additional funding.

Helus Pharma is burning $42.6M per quarter running two simultaneous Phase 3 trials of HLP003, a deuterated psilocybin analog for major depressive disorder, with $157M on hand and no revenue. The thesis resolves on whether APPROACH Phase 3 topline data confirms efficacy sufficient to anchor the 2028 NDA, and whether the company can raise additional capital before cash is exhausted. The central risk is that single-arm or Phase 2-grade precedent does not apply here — HLP003 requires two clean randomized pivotals, and a miss or partial signal on APPROACH would derail both the NDA timeline and financing capacity.